Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cilansetron: Phase III data

In a 6-month double-blind international Phase III study in 792 patients, significantly more patients receiving cilansetron reported

Read the full 179 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE